aureu
show
trend
toward
decreas
incid
nosocomi
aureu
infect
summari
staphylococcu
aureu
common
caus
postop
wound
infect
nasal
colon
organ
import
factor
develop
infect
treatment
mupirocin
erad
organ
short
term
prophylact
treatment
colon
patient
may
prevent
postop
aureu
infect
doubleblind
random
placebocontrol
trial
perform
determin
whether
nasal
mupirocin
administ
preoper
aureu
carrier
reduc
rate
sternal
leg
wound
infect
cardiac
surgeri
studi
enrol
patient
nasal
aureu
undergo
elect
cardiac
surgeri
st
michael
hospit
toronto
canada
patient
assess
infect
immedi
postop
period
two
month
later
two
hundr
fiftyseven
patient
includ
intentiontotreat
analysi
reanalys
accord
actual
treatment
appli
wound
infect
occur
mupirocin
recipi
placebo
recipi
p
seven
six
sternal
infect
respect
two
wound
infect
acquir
postop
mupirocin
group
neither
caus
aureu
placebo
group
three
nosocomi
wound
infect
two
aureu
bacteraemia
p
among
patient
receiv
mupirocin
clear
aureu
compar
patient
receiv
placebo
p
signific
differ
intentiontotreat
actual
treatment
group
prophylact
intranas
mupirocin
administ
aureu
carrier
reduc
rate
overal
surgic
site
infect
wound
infect
contribut
substanti
morbid
mortal
follow
cardiothorac
surgeri
deep
chest
infect
mortal
center
diseas
control
prevent
estim
surgic
infect
risk
associ
cardiothorac
procedur
deep
superfici
chest
infect
implic
case
leg
wound
infect
may
complic
case
econom
impact
postop
wound
infect
substanti
staphylococcu
aureu
common
microorgan
respons
wound
infect
caus
deep
sternal
infect
aureu
found
anterior
nare
asymptomat
carriag
common
colon
appear
major
factor
develop
infect
studi
examin
effect
nasal
colon
cardiothorac
wound
infect
suggest
major
independ
risk
factor
infect
author
previous
report
similar
result
show
aureu
carrier
develop
sternal
wound
infect
due
aureu
compar
noncarri
due
aureu
p
possibl
erad
nasal
aureu
may
prevent
surgic
wound
infect
topic
mupirocin
agent
choic
elimin
nasal
aureu
clinic
trial
conduct
determin
whether
preoper
intranas
mupirocin
appli
colon
patient
would
decreas
rate
aureu
wound
infect
affect
overal
infect
rate
cardiothorac
surgeri
colon
patient
enrol
studi
give
inform
consent
patient
random
receiv
either
mupirocin
ointment
identicalappear
placebo
administ
intranas
qtip
cotton
applic
vestibul
nare
twice
daili
seven
day
surgeri
mupirocin
contain
base
polyethylen
glycol
polyethylen
glycol
placebo
contain
base
random
number
comput
gener
ratio
mupirocin
placebo
code
avail
research
pharmacist
research
assist
contact
patient
directli
screen
side
effect
standard
preoper
clinic
practic
includ
full
shower
bath
chlorhexidin
antisept
soap
h
preoper
surgic
site
cleans
chlorhexdin
solut
isopropyl
alcohol
preoper
administr
routin
antibiot
prophylaxi
start
surgeri
antibiot
prophylaxi
consist
cefazolin
g
everi
h
clindamycin
penicillin
allergi
h
steril
cotton
swab
starswab
starplex
scientif
ontario
canada
moisten
steril
water
rub
along
entir
inner
surfac
nostril
plate
blood
agar
aureu
cultur
use
standard
laboratori
techniqu
nasal
cultur
obtain
two
week
surgeri
admiss
prior
surgeri
wound
swab
aspir
obtain
postop
asept
condit
wound
evid
inflamm
red
tender
swell
fluctuanc
intraop
wound
cultur
obtain
patient
surgic
wound
drainag
debrid
blood
cultur
obtain
febril
septic
patient
prospect
wound
surveil
carri
research
assist
review
microbiolog
log
nurs
report
detect
potenti
wound
infect
biweekli
basi
patient
treat
equal
research
assist
unawar
random
assign
surgeon
complet
formal
postdischarg
surveil
six
eight
week
surgeri
gener
practition
gp
patient
contact
telephon
twice
monthli
ensur
absenc
wound
infect
follow
discharg
addit
patient
ask
telephon
investig
develop
sign
infect
wound
infect
classifi
superfici
deep
deep
organ
space
infect
accord
nosocomi
infect
surveil
system
definit
surgic
site
infect
ssi
defin
occurr
one
follow
within
eight
week
surgeri
presenc
exud
wound
edg
wound
erythemat
beyond
cm
margin
wound
cultur
yield
pathogen
sign
inflamm
physician
state
medic
record
surgic
site
infect
corrobor
one
list
criteria
author
previou
studi
show
risk
aureu
sternal
infect
untreat
carrier
confid
interv
ci
wherea
risk
mupirocintr
patient
ci
thu
order
achiev
alpha
error
power
patient
would
need
group
onetail
test
patient
would
need
twotail
test
rate
wound
infect
surgic
site
primari
endpoint
secondari
endpoint
rate
aureu
infect
rate
overal
nosocomi
infect
nosocomi
aureu
infect
rate
nasal
aureu
clearanc
rate
death
complic
due
infect
patient
initi
analys
accord
intentiontotreat
actual
treatment
appli
data
analys
use
spss
categor
variabl
compar
univari
analysi
use
chisquar
test
fisher
exact
test
continu
variabl
analys
use
student
ttest
mannwhitney
test
variabl
deem
clinic
import
use
covari
logisticregress
analysi
evalu
effect
outcom
test
twotail
p
valu
less
consid
clinic
signific
blind
maintain
analysi
pharmacist
divid
treatment
group
b
two
hundr
sixtysix
patient
elig
studi
three
elimin
prior
random
studi
drug
dispens
remain
patient
random
mupirocin
placebo
five
exclud
analysi
due
cancel
surgeri
four
mupirocin
group
one
placebo
group
one
patient
exclud
intentiontotreat
analysi
alon
clear
treatment
random
use
mupirocin
initi
patient
includ
intentiontotreat
analysi
receiv
mupirocin
receiv
placebo
patient
placebo
group
use
mupirocin
well
instead
placebo
three
patient
reanalys
mupirocin
group
actual
treatment
analysi
one
patient
placebo
group
use
dispens
therapi
reanalys
group
followup
complet
patient
two
group
similar
respect
demograph
characterist
premorbid
ill
preand
postop
complic
care
tabl
chronic
obstruct
pulmonari
diseas
copd
significantli
preval
mupirocin
group
compar
placebo
group
vs
p
overal
nasal
carriag
aureu
elimin
patient
receiv
mupirocin
patient
receiv
placebo
p
tabl
initi
intentiontotreat
analysi
overal
rate
infect
p
seven
six
sternal
infect
mupirocin
placebo
group
respect
tabl
ii
odd
ratio
infect
adjust
diabet
smoke
hypertens
copd
immunosuppress
obes
ci
total
number
nosocomi
wound
infect
two
mupirocin
group
three
placebo
group
p
total
number
aureu
infect
five
four
mupirocin
placebo
group
respect
howev
nosocomi
aureu
infect
lead
bacteraemia
seriou
complic
includ
death
occur
placebo
group
n
p
tabl
ii
iii
infect
n
infect
group
mupirocin
group
leg
infect
report
gp
followup
microbiolog
data
signific
morbid
tabl
iii
infect
develop
eight
patient
colon
aureu
time
surgeri
compar
patient
clear
aureu
statist
signific
differ
patient
repeat
nasal
swab
four
infect
patient
took
mupirocin
initi
reanalys
mupirocin
group
signific
differ
note
independ
predictor
infect
adjust
age
sex
diabet
hypertens
cancer
renal
diseas
smoke
copd
obes
p
aureu
colon
statu
time
surgeri
includ
multivari
regress
analysi
predict
infect
patient
undergo
oper
outbreak
sever
acut
respiratori
syndrom
toronto
signific
delay
treatment
surgeri
patient
rescreen
preoper
four
death
mupirocin
group
five
death
placebo
group
none
death
mupirocin
group
attribut
infect
wherea
one
death
placebo
group
directli
relat
aureu
infect
one
death
result
pneumonia
escal
multiorgan
failur
none
aureu
isol
either
nasal
wound
cultur
meticillin
resist
advers
effect
report
either
mupirocin
placebo
colon
aureu
associ
subsequ
infect
mupirocin
topic
antibacteri
ointment
demonstr
benefit
erad
colon
aureu
recent
metaanalysi
topic
mupirocin
patient
undergo
dialysi
indic
use
therapi
reduc
rate
aureu
infect
efficaci
mupirocin
prevent
aureu
postop
infect
howev
remain
controversi
sever
retrospect
case
control
studi
report
lower
rate
ssi
among
patient
receiv
preoper
mupirocin
copd
chronic
obstruct
pulmonari
diseas
cabg
coronari
arteri
bypass
graft
number
indic
mean
ae
standard
deviat
b
p
comparison
mupirocin
placebo
group
c
p
comparison
mupirocin
placebo
group
postop
nasal
cultur
obtain
patient
mupirocin
group
patient
placebo
group
compar
histor
control
random
control
studi
confirm
result
random
control
doubleblind
studi
signific
reduct
total
number
ssi
aureusrel
infect
mupirocin
group
howev
two
case
aureu
bacteraemia
occur
placebo
group
result
similar
two
recent
randomizedcontrol
studi
caution
studi
enrol
consecut
patient
wherea
colon
aureu
enrol
present
studi
perl
et
al
enrol
patient
undergo
differ
type
surgeri
prophylact
intranas
mupirocin
reduc
aureu
ssi
significantli
decreas
rate
nosocomi
aureu
infect
among
patient
aureu
carrier
similarli
kalmeij
et
al
enrol
patient
undergo
orthopaed
surgeri
patient
colon
aureu
baselin
although
aureu
infect
rate
five
time
lower
mupirocin
group
ssi
rate
durat
hospit
reduc
significantli
present
studi
limit
ssi
rate
aureu
probabl
low
detect
differ
sampl
size
enrol
also
true
random
studi
retrospect
expect
ssi
rate
subject
colon
aureu
overestim
anoth
factor
import
wound
infect
report
gp
confirm
investig
corrobor
microbiolog
cultur
moreov
surpris
placebo
patient
clear
nasal
aureu
colon
surgeri
could
result
low
aureu
ssi
rate
result
contrast
random
studi
nasal
carriag
aureu
elimin
patient
treat
mupirocin
treat
placebo
studi
perl
et
al
resid
longtermcar
facil
mupirocin
erad
aureu
colon
patient
compar
placebo
group
reason
high
rate
nasal
aureu
elimin
placebo
group
present
studi
unclear
note
mupirocin
could
purchas
without
prescript
ontario
prior
thu
rais
question
complianc
assign
treatment
regimen
one
main
concern
widespread
use
prophylact
mupirocin
develop
resist
report
mainli
longterm
use
patient
dialysi
possibl
sourc
bia
trial
subject
endpoint
lack
blind
analysi
result
present
studi
maintain
blind
analysi
complet
conclus
studi
fail
show
benefit
mupirocin
reduc
ssi
aureu
infect
subject
nasal
aureu
colon
undergo
cardiothorac
surgeri
futur
random
studi
perform
highrisk
patient
aureu
colon
ie
establish
risk
factor
diabet
obes
smoke
etc
erad
may
effect
prevent
infect
larg
multicentr
trial
current
evid
support
mupirocin
use
routin
surgic
prophylaxi
